INSP stock forecast, quote, news & analysis
Inspire Medical Systems Inc operates as a medical technology company... Show more
Inspire Medical Systems (INSP) Stock Analysis: Navigating Reimbursement Headwinds
Key Takeaways
- INSP shares have traded near 52-week lows around $65, down over 60% in the past year amid reimbursement uncertainties.
- Preliminary Q4 2025 revenue beat estimates at $268.9-$269.1 million, up 12% year-over-year, with full-year 2025 at $911.8-$912.0 million.
- Initial 2026 revenue guidance projects 10-11% growth to $1.003-$1.013 billion, excluding potential reimbursement uplift.
- Multiple analyst downgrades in January due to Medicare coding issues, though consensus target remains around $124-$133.
- Q4 earnings due February 11, with expectations for EPS beat at $0.68 and revenue of $266 million.
- Strong adoption of Inspire V system supports procedure growth despite near-term challenges.
Current Market Snapshot
In recent trading sessions, Inspire Medical Systems (INSP) stock has hovered near its 52-week low, reflecting investor caution amid evolving reimbursement dynamics in the obstructive sleep apnea treatment market. The shares have experienced heightened volatility, with pressure from Medicare coding revisions offsetting solid procedural momentum and the ongoing rollout of the next-generation Inspire V system. Broader medical device sector sentiment and macroeconomic factors have contributed to the subdued performance, as analysts reassess near-term growth trajectories. Trading volumes have elevated during key news events, underscoring focus on upcoming earnings and regulatory clarity. Despite the pullback, the company's robust cash position and expanding addressable market provide a foundation for potential stabilization in the latest market cycle.
Recent Developments Driving INSP Price Action
Inspire Medical Systems, a leader in neurostimulation therapies for obstructive sleep apnea, has faced a turbulent period marked by regulatory hurdles and leadership transitions, directly impacting its stock trajectory.
On January 12, 2026, the company released preliminary unaudited results showing Q4 2025 revenue of $268.9-$269.1 million, surpassing consensus estimates of $262 million and reflecting 12% year-over-year growth driven by strong Inspire V adoption. Full-year 2025 revenue landed at $911.8-$912.0 million, up 14%. Concurrently, Inspire provided initial 2026 guidance of $1.003-$1.013 billion, implying 10-11% growth but excluding any benefits from pending reimbursement enhancements pending coding clarification. This conservative outlook initially disappointed investors, contributing to share weakness despite the Q4 beat.
The appointment of Matt Osberg as Executive Vice President and CFO effective January 19, 2026, signaled strategic continuity, with current CFO Richard Buchholz transitioning post-10-K filing. This move coincided with the preliminary results but did little to stem downward momentum.
Reimbursement uncertainties dominated sentiment. A CMS correction on coding prompted Oppenheimer's downgrade to Market Perform from Outperform on January 22, followed by Truist's shift to Hold from Buy with a $96 target, citing eroded upside from coding setbacks. RBC Capital downgraded to Sector Perform from Outperform on January 26-27, slashing its target to $90 from $175 due to persistent Medicare headwinds. Earlier, in December 2025, Medicare Administrative Contractor (MAC) "flip-flops" on CPT codes triggered a 19.6% single-day drop on December 18, amplifying volatility into January.
These developments fueled a roughly 30% decline over recent weeks, pushing shares to a 52-week low of $64.46 on February 9, 2026. Analyst consensus holds at Hold/Outperform, with an average price target of $124-$133 implying significant upside, though ratings reflect caution. Institutional activity included New York State Common Retirement Fund trimming its stake in early February. Q3 2025 results in November had shown resilience with $224.5 million revenue (up 10.5%) and EPS beats, but prior guidance cuts lingered.
Class action lawsuits in early January alleging misleading statements on demand added minor pressure, though core drivers remain procedural growth and reimbursement resolution. Recent sessions saw modest rebounds amid pre-earnings positioning.
2026 Outlook and Key Factors to Monitor
As Inspire Medical Systems advances through 2026, investors should track resolution of Medicare coding and reimbursement clarity, which could unlock procedural acceleration beyond the initial 10-11% revenue growth guidance. The Inspire V system's broader adoption, now at over 75% of implanting centers, positions the company to capture pent-up demand once onboarding completes by mid-year. Management highlights robust clinical momentum and expanding center network as long-term drivers in the underserved OSA market.
Key opportunities include potential reimbursement tailwinds post-coding fixes, enabling higher procedure volumes and margins. Competitive positioning against emerging GLP-1 therapies for sleep apnea, alongside macroeconomic healthcare spending trends, warrants attention. Cost controls amid gross margins around 85% and a strong balance sheet with $322 million cash provide resilience.
Risks encompass prolonged regulatory delays, slower-than-expected V system ramp-up, and litigation overhangs. Analyst growth estimates project modest sales expansion at 7.32% for 2026, with EPS trajectory tied to execution. Monitoring Q1 earnings post-February 11 report, MAC decisions, and CMS updates will be pivotal for assessing sustained recovery potential in this innovative medtech space.
INSP's Stochastic Oscillator is sitting in oversold zone for 9 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where INSP's RSI Oscillator exited the oversold zone, of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where INSP advanced for three days, in of 292 cases, the price rose further within the following month. The odds of a continued upward trend are .
INSP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on April 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INSP as a result. In of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for INSP turned negative on May 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INSP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for INSP entered a downward trend on May 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.547) is normal, around the industry mean (12.436). P/E Ratio (9.666) is within average values for comparable stocks, (50.387). INSP's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.660). INSP has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.023). P/S Ratio (1.364) is also within normal values, averaging (35.253).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. INSP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INSP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of implantable neurostimulation systems to treat obstructive sleep apnea
Industry MedicalNursingServices